FDA Adverse Event Injury Summary report: N

PULSE GEN MODEL UNK

MDR report key: 3122253 · Received May 21, 2013

Report

Report Number
1644487-2013-01495
Event Type
Injury
Date Received
May 21, 2013
Date of Event
January 1, 2012
Report Date
April 29, 2013
Manufacturer
CYBERONICS, INC.
Product Code
LYJ
PMA / PMN Number
P970003
Removal / Correction Number
NA
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

RYZI M, BRAZDIL M, NOVAK Z, CHRASTINA J, OSLEJSKOVA H, REKTOR I, ET AL. LONG-TERM VAGUS NERVE STIMULATION IN CHILDREN WITH FOCAL EPILEPSY. ACTA NEUROL SCAND. 2012. HTTP://WWW.NCBI.NLM.NIH.GOV/PUBMED/22994298.

Description of Event or Problem · 1

AN ARTICLE ENTITLED ¿LONG-TERM VAGUS NERVE STIMULATION IN CHILDREN WITH FOCAL EPILEPSY¿ WAS RECEIVED. THE ARTICLE REVIEWED ONE AND TWO YEAR EFFICACIES OF 15 PATIENTS IMPLANTED WITH A THERAPY SYSTEM. OF THE 15 PATIENTS, 7 WERE RESPONDERS AT ONE YEAR AFTER IMPLANT, NINE WERE RESPONDERS AT TWO YEARS AFTER IMPLANT, AND NINE WERE RESPONDERS AT FIVE YEARS AFTER IMPLANT. INITIAL SETTINGS WERE PROVIDED. THE OUTPUT CURRENT WAS INCREASED IN TWO WEEK INCREMENTS OF 0.25 MA TO A TARGET INTENSITY OF 01.50 MA TO 2.0 MA DEPENDING ON EFFICACY AND THE PRESENCE OF SIDE EFFECTS. RAPID CYCLES (ON TIME: 3.0 SECONDS, OFF TIME: 1.8 MINUTES AND ON TIME: 7 SECONDS, OFF TIME: 18 SECONDS) WAS USED IN ALL PATIENTS WHO WERE CLASSIFIED AS NON-RESPONDER AT ONE YEAR. MEDICATIONS WERE KEPT UNCHANGED DURING THE FIRST SIX MONTHS. THE ARTICLE CONCLUDED THAT VAGUS NERVE STIMULATION IS AN EFFECTIVE METHOD OF TREATING CHILDREN WITH REFRACTORY FOCAL EPILEPSY. IT LED TO A SUBSTANTIAL DECREASE IN THE NUMBER AND DURATION OF URGENT HOSPITALIZATIONS. THE ARTICLE INDICATED THAT ONE PATIENT EXPERIENCED SEVERE ADVERSE EFFECTS REQUIRING EXPLANT OF THE DEVICE. THE PATIENT EXPERIENCED REPETITIVE ATTACKS OF CARDIAC ASYSTOLIA, SOMETIMES ASSOCIATED WITH SYNCOPE AT THE TIME WHEN THE DEVICE WAS SWITCHED ON. THE SYNCOPES STARTED AFTER MORE THAN ONE YEAR OF STIMULATION. THE ASYSTOLE WAS STRICTLY RELATED TO THE ON STATUS OF THE DEVICE AND WAS NOT RELATED TO PATIENT SEIZURES.¿ THIS WAS PROVIDED BY VIDEO-EEG MONITORING. THE PATIENT DID NOT RESPONSE TO VNS; THEREFORE, THE OUTPUT CURRENT WAS NOT ADJUSTED. THE DISCONTINUATION OF VNS LED TO THE COMPLETE CESSATION OF THESE SYMPTOMS. THE CARDIOLOGICAL INVESTIGATIONS PERFORMED ON THIS PATIENT BOTH PRE-OPERATIVELY AND POST-OPERATIVELY (DURING THE OFF TIMES) REVEALED NO ABNORMALITIES. OTHER SEVERE ADVERSE EFFECTS WERE NOT OBSERVED. THE EXPLANT DUE TO CARDIAC EVENTS IS CAPTURED IN MFR REPORT #1644487-2013-01439. URGENT HOSPITALIZATIONS WERE ALSO REPORTED FOR NINE PATIENTS IN THE POST-OPERATIVE PERIOD. THIS WAS DEFINED AS HOSPITALIZATION BECAUSE OF AN INCREASE IN SEIZURE FREQUENCY WITH A CHANGE OR ADJUSTMENT IN THE LONG-TERM AED TREATMENT OR BECAUSE OF AN ADVERSE EVENT, A COMPLICATION OF THE EPILEPSY ITSELF, OR AN AED TREATMENT THAT LEAD TO ANY PERMANENT THERAPEUTIC TREATMENTS. THIS REPORT CAPTURES THE URGENT HOSPITALIZATION FOR AN INCREASE IN SEIZURE FREQUENCY FOR PATIENT 5 OF 9. ADDITIONAL REPORTS ARE CAPTURED IN MFR REPORT #1644487-2013-01490, MFR REPORT #1644487-2013-01491, MFR REPORT #1644487-2013-01493, MFR REPORT # 1644487-2013-01494, MFR REPORT #1644487-2013-01496, MFR REPORT #1644487-2013-01497, MFR REPORT #1644487-2013-01498, MFR REPORT #1644487-2013-01499 THE ARTICLE ALSO NOTED THAT COUGH, HOARSENESS, AND MILD DYSPHAGIA WERE OBSERVED IN 12 OF THE 15 PATIENTS REVIEWED. IN NONE OF THESE PATIENT¿S WAS THE SEVERE EFFECT A REASON FOR DISCONTINUATION OF VNS, AND THE EFFECT RESOLVED COMPLETED BY THE NEXT VISIT.

Description of Event or Problem · 1

ADDITIONAL INFORMATION WAS RECEIVED THAT ALL OF THE REPORTED ADVERSE EVENTS (EXCEPT FOR THE CARDIAC EVENT) WERE MILD, TEMPORARY, AND OVERALL IN LINE WITH THE EXPERIENCE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
224410 PULSE GEN MODEL UNK GENERATOR LYJ CYBERONICS, INC. NI NI

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention